Single-molecule analysis reveals widespread structural variation in multiple myeloma
暂无分享,去创建一个
Deepayan Sarkar | Yang Li | Shiguo Zhou | Michael Place | Jian Ma | Peiman Hematti | Emery H Bresnick | David C Schwartz | D. Schwartz | Jian Ma | Steve Goldstein | K. Potamousis | Michael Place | D. Sarkar | E. Bresnick | N. Callander | Yang Li | P. Hematti | Jaehyup Kim | Steven Goldstein | Natalie S Callander | F. Asimakopoulos | Konstantinos Potamousis | Aditya Gupta | Claire Flanagan | Michael A Newton | Fotis Asimakopoulos | Michael A. Newton | Jaehyup Kim | Claire E Flanagan | Aditya Gupta | Shiguo Zhou
[1] B. Barlogie,et al. The growth fraction of human myeloma cells. , 1981, Blood.
[2] Bradley P. Coe,et al. Genome structural variation discovery and genotyping , 2011, Nature Reviews Genetics.
[3] G. Parmigiani,et al. Heterogeneity of genomic evolution and mutational profiles in multiple myeloma , 2014, Nature Communications.
[4] S. Miyamoto,et al. Perillyl alcohol inhibits a calcium-dependent constitutive nuclear factor-kappaB pathway. , 2005, Cancer research.
[5] Thomas W. Mühleisen,et al. Common variation at 3p22.1 and 7p15.3 influences multiple myeloma risk , 2011, Nature Genetics.
[6] Tatiana Popova,et al. Supplementary Methods , 2012, Acta Neuropsychiatrica.
[7] M. Hurles,et al. Copy number variation in human health, disease, and evolution. , 2009, Annual review of genomics and human genetics.
[8] P. L. Bergsagel,et al. Molecular pathogenesis of multiple myeloma and its premalignant precursor. , 2012, The Journal of clinical investigation.
[9] A. Shilatifard,et al. The super elongation complex (SEC) and MLL in development and disease. , 2011, Genes & development.
[10] S. Rajkumar,et al. The current status of minimal residual disease assessment in myeloma , 2014, Leukemia.
[11] O. Cope,et al. Multiple myeloma. , 1948, The New England journal of medicine.
[12] A. McKenna,et al. Widespread genetic heterogeneity in multiple myeloma: implications for targeted therapy. , 2014, Cancer cell.
[13] Thomas W. Mühleisen,et al. Common variation at 3q26.2, 6p21.33, 17p11.2 and 22q13.1 influences multiple myeloma risk , 2013, Nature Genetics.
[14] G. Morgan,et al. A compendium of myeloma-associated chromosomal copy number abnormalities and their prognostic value. , 2010, Blood.
[15] O. Abdel-Wahab,et al. The role of mutations in epigenetic regulators in myeloid malignancies , 2012, Nature Reviews Cancer.
[16] David C. Schwartz,et al. High-resolution human genome structure by single-molecule analysis , 2010, Proceedings of the National Academy of Sciences.
[17] M. Gerstein,et al. CNVnator: an approach to discover, genotype, and characterize typical and atypical CNVs from family and population genome sequencing. , 2011, Genome research.
[18] Philip M. Kim,et al. Paired-End Mapping Reveals Extensive Structural Variation in the Human Genome , 2007, Science.
[19] Deepayan Sarkar,et al. Discovery of structural alterations in solid tumor oligodendroglioma by single molecule analysis , 2013, BMC Genomics.
[20] K. Vanderkerken,et al. The role of the insulin-like growth factor 1 receptor axis in multiple myeloma , 2009, Archives of physiology and biochemistry.
[21] R. Wilson,et al. BreakDancer: An algorithm for high resolution mapping of genomic structural variation , 2009, Nature Methods.
[22] G. Morgan,et al. Characterization of IGH locus breakpoints in multiple myeloma indicates a subset of translocations appear to occur in pregerminal center B cells. , 2013, Blood.
[23] Kai Ye,et al. Pindel: a pattern growth approach to detect break points of large deletions and medium sized insertions from paired-end short reads , 2009, Bioinform..
[24] C Bifulco,et al. The A-Myb transcription factor is a marker of centroblasts in vivo. , 1998, Journal of immunology.
[25] David C. Schwartz,et al. An algorithm for assembly of ordered restriction maps from single DNA molecules , 2006, Proceedings of the National Academy of Sciences.
[26] G. Morgan,et al. Deletions of CDKN2C in Multiple Myeloma: Biological and Clinical Implications , 2008, Clinical Cancer Research.
[27] E. Terpos,et al. No evidence of mutations of the PSMB5 (beta-5 subunit of proteasome) in a case of myeloma with clinical resistance to Bortezomib. , 2006, Leukemia research.
[28] Asta Försti,et al. The CCND1 870G>A polymorphism is a risk factor for t(11;14)(q13;q32) multiple myeloma , 2013, Nature Genetics.
[29] D. Dingli,et al. Improved survival in multiple myeloma and the impact of novel therapies. , 2008, Blood.
[30] J. Carpten,et al. Whole-genome sequencing of multiple myeloma from diagnosis to plasma cell leukemia reveals genomic initiating events, evolution, and clonal tides. , 2012, Blood.
[31] David C. Schwartz,et al. Statistical Significance of Optical Map Alignments , 2012, J. Comput. Biol..
[32] Juan J de Pablo,et al. A microfluidic system for large DNA molecule arrays. , 2004, Analytical chemistry.
[33] David C. Schwartz,et al. A large, complex structural polymorphism at 16p12.1 underlies microdeletion disease risk , 2010, Nature Genetics.
[34] KyungMann Kim,et al. Bone marrow stromal cells from multiple myeloma patients uniquely induce bortezomib resistant NF-κB activity in myeloma cells , 2010, Molecular Cancer.
[35] Y. Pekarsky,et al. Tcl1 as a model for lymphomagenesis. , 2004, Hematology/oncology clinics of North America.
[36] S. Rajkumar,et al. Multiple myeloma: 2012 update on diagnosis, risk‐stratification, and management , 2012, American journal of hematology.
[37] David C. Schwartz,et al. Refinement of optical map assemblies , 2006, Bioinform..
[38] S. Lonial,et al. PI3 kinase/AKT pathway as a therapeutic target in multiple myeloma. , 2007, Future oncology.
[39] Yi Yang,et al. Alignment of Optical Maps , 2005, RECOMB.
[40] Trevor J Pugh,et al. Initial genome sequencing and analysis of multiple myeloma , 2011, Nature.